You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020151014
Dec 20201806
Jan 20211801
Feb 20211803
Mar 20213905
Apr 20211205
May 2021902
Jun 2021004
Jul 2021107
Aug 2021003
Sep 2021001
Oct 202116016
Nov 202120015
Dec 20211201
Jan 2022601
Feb 20224402
Mar 20226605
Apr 20223202
May 20222200
Jun 20225400
Jul 2022801
Aug 20222402
Sep 20221205
Oct 2022600
Nov 20221001
Dec 20222601
Jan 20231400
Feb 20232000
Mar 2023800
Apr 20232003
May 20232801
Jun 2023400
Jul 2023402
Aug 20232201
Sep 2023600
Oct 20231202
Nov 20231401
Dec 20232000
Jan 20242001
Feb 20241400
Mar 20242001
Apr 2024802
May 20242201
Jun 20242901
Jul 20242202
Aug 20242203
Sep 20241801
Total9710125